PubRank

Stephen D Hall

Author PubWeight™ 85.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003 3.71
2 Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 3.63
3 Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 3.27
4 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2004 1.89
5 Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003 1.65
6 Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol 2012 1.58
7 Airflows around oxygen masks: A potential source of infection? Chest 2006 1.53
8 Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002 1.52
9 Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther 2004 1.51
10 The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004 1.44
11 Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest 2009 1.41
12 Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 2011 1.38
13 GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage 2005 1.35
14 Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002 1.28
15 Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006 1.27
16 Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006 1.26
17 Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008 1.18
18 Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010 1.18
19 The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003 1.13
20 Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest 2006 1.13
21 Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003 1.11
22 Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 2009 1.11
23 Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med 2007 1.08
24 Association between the CYP3A5 genotype and blood pressure. Hypertension 2004 1.07
25 Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002 1.06
26 Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007 1.04
27 Sustained neuronal activity generated by glial plasticity. J Neurosci 2011 1.03
28 The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006 1.02
29 The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos 2002 1.01
30 The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS 2008 0.99
31 Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 2009 0.99
32 Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005 0.99
33 Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 2007 0.99
34 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004 0.96
35 Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos 2007 0.96
36 Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 2006 0.95
37 Literature mining on pharmacokinetics numerical data: a feasibility study. J Biomed Inform 2009 0.93
38 In vivo real-time 3-D intracardiac echo using PMUT arrays. IEEE Trans Ultrason Ferroelectr Freq Control 2014 0.92
39 Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 2008 0.91
40 A general linear model for MEG beamformer imaging. Neuroimage 2004 0.91
41 Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg 2013 0.90
42 Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos 2012 0.89
43 Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest 2007 0.89
44 Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol 2012 0.88
45 Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 2005 0.88
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 2005 0.88
47 Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos 2002 0.88
48 Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology 2005 0.87
49 The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 2002 0.87
50 Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model 2013 0.86
51 A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn 2009 0.86
52 Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 2005 0.85
53 Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans. J Neurosci 2013 0.85
54 Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control 2007 0.85
55 Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit 2008 0.84
56 Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis 2012 0.83
57 Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2007 0.83
58 Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009 0.83
59 Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005 0.83
60 Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol 2012 0.82
61 Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 2008 0.82
62 Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 2013 0.82
63 Primary and secondary somatosensory cortex responses to anticipation and pain: a magnetoencephalography study. Eur J Neurosci 2011 0.82
64 A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 2008 0.82
65 Irreversible enzyme inhibition kinetics and drug-drug interactions. Methods Mol Biol 2014 0.81
66 A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models. J Biopharm Stat 2009 0.81
67 The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos 2004 0.81
68 The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine. Drug Metab Dispos 2013 0.81
69 CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos 2013 0.80
70 A multimodal perspective on the composition of cortical oscillations. Front Hum Neurosci 2013 0.80
71 Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023). J Pharm Sci 2014 0.79
72 Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos 2010 0.79
73 Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 2012 0.78
74 A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009 0.78
75 Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos 2008 0.77
76 Drug-drug interaction prediction assessment. J Biopharm Stat 2009 0.77
77 Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. J Acquir Immune Defic Syndr 2010 0.76
78 Live volumetric imaging (LVI) intracardiac ultrasound catheter. Cardiovasc Revasc Med 2013 0.76
79 Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 2011 0.76
80 QT effect of semagacestat at therapeutic and supratherapeutic doses. Int J Clin Pharmacol Ther 2012 0.75
81 The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. Drug Metab Dispos 2012 0.75